

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7338924

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
GLYKOS FINLAND OY	02/28/2012
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.
<b>Street Address:</b>	131 FRONT STREET
<b>City:</b>	HAMILTON
<b>State/Country:</b>	BERMUDA
<b>Name:</b>	GLYKOS FINLAND OY
<b>Street Address:</b>	VIIKINKAARI 6
<b>City:</b>	HELSINKI
<b>State/Country:</b>	FINLAND
<b>Postal Code:</b>	00790
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17529931
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	ip@remotedocket.com
<b>Correspondent Name:</b>	PATRICK J. HALLORAN
<b>Address Line 1:</b>	3141 MUIRFIELD ROAD
<b>Address Line 4:</b>	CENTER VALLEY, PENNSYLVANIA 18034
<b>ATTORNEY DOCKET NUMBER:</b>	NOVA-0002-WO-US-CON4
<b>NAME OF SUBMITTER:</b>	PATRICK J. HALLORAN
<b>SIGNATURE:</b>	/Patrick J. Halloran/
<b>DATE SIGNED:</b>	05/19/2022
<b>Total Attachments: 2</b>	
source=4-NOVA0002-GLYKOS-NOVAGGLYKOS-X#page1.tif	
source=4-NOVA0002-GLYKOS-NOVAGGLYKOS-X#page2.tif	

(joint)

Attorney Docket No. 619673001900

### ASSIGNMENT

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,

Glykos Finland Oy, an organization whose address is Viikinkaari 6, Helsinki, FINLAND, 00790, (hereinafter referred to as the "**ASSIGNOR**"), do hereby sell, assign and transfer to

Novartis International Pharmaceutical Ltd., a Bermuda corporation with its principal offices at 131 Front Street, Hamilton, BERMUDA, and to Glykos Finland Oy, a Finnish limited liability company with its principal offices at Viikinkaari 6, Helsinki, FINLAND, 00790, (hereinafter referred to as the "**ASSIGNEES**") and their successors, assigns and legal representatives,

all of **ASSIGNOR'S** right, title and interest (obtained directly or indirectly from Christopher LANDOWSKI, Anne HUUSKONEN, Juhani SAARINEN, Ann WESTERHOLM-PARVINEN, Anne KANERVA, Jari NATUNEN, Anna-Liisa HÄNNINEN, Noora SALOVUORI, Merja PENTTILÄ and Markku SALOHEIMO) for all countries of the world in and to (1) all of **ASSIGNOR'S** inventions and discoveries described in the patent application(s) titled

#### PROTEASE DEFICIENT FILAMENTOUS FUNGAL CELLS AND METHODS OF USE THEREOF

and filed in the United States Patent and Trademark Office on January 5, 2012 and accorded Application Number 61/583,559, (2) the patent application identified in (1), (3) the right to file patent applications on said inventions and discoveries in the name of **ASSIGNEES** or their designees or in our names, at their election and in accordance with applicable law in all countries and regions, (4) for all patent applications, all rights of priority based upon the patent application identified in (1) in all countries and regions under the Paris Convention for the Protection of Industrial Property, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the patent application identified in (1) is a provisional patent application, under 35 USC 119(e), (5) all patent applications in all countries and regions claiming the priority of the patent application identified in (1) and only one or more inventions and/or discoveries disclosed in said patent application (including national stages of any international patent application), (6) all continuations and divisions of any non-provisional patent application identified in (1) and any patent application within the scope of (5) (including further continuations and divisions such as, but not limited to, continuations of continuations and continuations of divisions), ((2), (5) and (6) hereinafter referred to collectively as "patent applications"), (7) all patents that are granted on any of said patent applications, (8) all registrations and confirmations of, and importation certificates based upon, one or more of said patents and applications for such registrations, confirmations and importation certificates and (9) all reissues, renewals and extensions of said patents, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said **ASSIGNEES** and their successors, assigns and legal representatives to the full ends of the terms for which said patents, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.


And **ASSIGNOR** hereby covenants and agrees that **ASSIGNOR** will, at any time, (i) upon the request, but at the expense, of **ASSIGNEES** or their successors, assigns or legal representatives execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, patent applications, patents, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates and applications within the scope of (8) and (9) in **ASSIGNEES** or their successors, assigns or legal representatives, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual

sf-3098933

**PATENT**  
**REEL: 059956 FRAME: 0941**

property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of **ASSIGNEES** or their successors, assigns or legal representatives execute all additional patent applications within the scope of (5) and (6) and all applications within the scope of (8) and (9) and (iii) make all rightful oaths and declarations and do all lawful acts required for procuring the same or for aiding therein, without further compensation, but at the expense of **ASSIGNEES** or their successors, assigns or legal representatives.

Executed this 28 day of February, 2012.

 L.S.

Assignor  
Printed Name: Juhani SAARINEN  
Title: Chief Executive Officer  
Entity: Glykos Finland Oy

Witnessed this 28 day of February, 2012.

 L.S.

Witness  
Printed Name: TERO SATOMÄKI

sf-3098933